Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABVC BioPharmaABVC +2.46%17 Earnings per Share (Diluted) is $-0.39 as of Mar. 2026. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,168 Biotechnology companies, ABVC BioPharma ranks better than 89.04% on this metric.
ABVC BioPharma's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.06.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.39.
During the past 3 years, the average EPS without NRIGrowth Rate was 59.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 44.70% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 12.20% per year.
During the past 13 years, ABVC BioPharma's highest 3-Year average EPS without NRI Growth Rate was 98.20% per year. The lowest was -164.20% per year. And the median was 43.20% per year.
ABVC BioPharma (NAS:ABVC) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
ABVC BioPharma Earnings per Share (Diluted) Related Terms
ABVC BioPharma Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for ABVC BioPharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABVC vs GRCE, ELOX, INMB: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, ABVC BioPharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABVC BioPharma PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ABVC BioPharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where ABVC BioPharma's PE Ratio falls into.
ABVC BioPharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
ABVC BioPharma's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.39 mean?
ABVC BioPharma (ABVC) has a Earnings per Share (Diluted) of $-0.39 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on ABVC BioPharma and its competitors. According to the industry distribution chart, ABVC BioPharma ranks #128 out of 1168 companies in the Biotechnology industry, placing it in the top 11%.
Is ABVC BioPharma's Earnings per Share (Diluted) too high?
ABVC BioPharma's current Earnings per Share (Diluted) is $-0.39. Based on the distribution chart, ABVC BioPharma ranks #128 out of 1168 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Earnings per Share (Diluted) compare to GRCE and ELOX?
According to the Biotechnology industry distribution chart, ABVC BioPharma ranks #128 out of 1168 companies for Earnings per Share (Diluted). This places ABVC BioPharma in the top 11% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on ABVC BioPharma and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABVC BioPharma's current Earnings per Share (Diluted) is $-0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.26 — trading 44.7% above its estimated fair value. The current Earnings per Share (Diluted) is $-0.39. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Earnings per Share (Diluted) is $-0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABVC BioPharma (ABVC) Overvalued in 2026?
Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued.
The current stock price of $1.26 is trading 44.7% above its estimated GF Value™ of $0.87.
GuruFocus considers ABVC BioPharma to be Significantly Overvalued.
Key valuation signals for ABVC:
Earnings per Share (Diluted): $-0.39
GF Value™: $0.87 vs. price of $1.26 (44.7% above fair value)
No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score
Get the complete analysis for ABVC
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABVC has been successfully added to your 
